Supplementary Appendix 5 (on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract Recommendations for pharmacologic interventions Active PsA in treatment-naive patients (Table 1 3 In treatment-naive patients with active PsA, a TNFi biologic agent is recommended over an OSM as a first-line option (Table 1 2 For treatment-naive patients with active PsA, the use of a TNFi biologic or OSM is recommended over an interleukin-17 inhibitor (IL-17i) or